Sotagliflozin Versus Empagliflozin Added to Metformin for Glycemic Control in Type 2 Diabetes
A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 140 participants.
Also called NCT07939750
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Phase 4
- Enrolled
- 140 participants
- Sponsor
- Allied Hospital Faisalabad
- Registry
-
NCT07939750
-
- Planned start
- (anticipated)
- Primary completion
- (anticipated)
- Completion
- (anticipated)
- Countries
- Pakistan
- Registry status
- Not yet recruiting
Technical summary
Registry record NCT07939750. Randomized; single masking; primary purpose treatment. Start 2026-12-01 (anticipated); primary completion 2027-12-01 (anticipated). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Sotagliflozin Versus Empagliflozin Added to Metformin for Glycemic Control in Type 2 Diabetes
- Condition
- Type 2 Diabetes Mellitus (DM)
- Intervention (Drug)
- Sotagliflozin
- Intervention (Drug)
- Empagliflozin (oral)
- Intervention (Drug)
- Metformin
- Lead sponsor
- Allied Hospital Faisalabad
Record details
- Record id
cardio:ct-nct07939750- Content hash
9a344812a9cd09423d6ded3554472c3afbd55c2ba7d424c31fc4f3725f05069d